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REVIEW
Malaria: an evaluation of the current state of
research on Pathogenesis and antimalarial
drugs 
Saheli Sadanand
Graduate School of Arts & Sciences, Department of Immunobiology, Yale University
School of Medicine, New Haven, Connecticut
This brief review provides an overview of the pathogenesis of malaria, the human immune
response to malaria, current methodology for malaria diagnosis, and current antimalarial
drug regimens. The review also provides a critical evaluation of the research directions in
the areas of drug design and vaccine design.
introduction
Malaria is inarguably the world’s most
devastating disease. It is endemic in sub-
Saharan Africa, South Asia, and parts of
South  America,  and  it  kills  more  than
800,000 people every year [1]. It is the
leading cause of death in children and di-
rectly and adversely affects economic de-
velopment.  In  spite  of  its  defined
pathogenesis and a number of available
treatments, the disease remains a huge eco-
nomic burden. This review will provide a
broad evaluation of the state of research on
the pathogenesis of and immune responses
to malaria as well as the efficacy of the cur-
rent repertoire of antimalarial drugs and the
best approaches for the development of
new antimalarial drugs.
Pathogenesis of Malaria
Malaria can be caused by any of five
species of the protist genus Plasmodium ―
P. vivax, P. ovale, P. malarie, P. falciparum,
and P. knowlesi. Plasmodium depends on
two  hosts  ―  a  female  mosquito  and  a
human ― to complete its life cycle.
The female Anopheles mosquito bites
an infected host, and gametocytes of the
parasite are released in the mosquito gut.
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which then form diploid zygotes that burrow
into the midgut epithelium and develop into
oocysts. The oocysts burst after one or two
weeks of incubation in the midgut and re-
lease  sporozoites  into  the  hemolymph.
These sporozoites invade the salivary glands
and are then transmitted to the bloodstream
of the next human that the mosquito bites. 
In the human host, the sporozoites mi-
grate to the liver and infect hepatocytes, using
these host cells to grow and form haploid
merozoites. This stage can take less than a
week, but often the parasites lie dormant in the
liver, leading to disease relapses weeks or
months following infection. The merozoites
exit the hepatocytes and infect erythrocytes,
using them as sites of asexual replication by
remodeling the erythrocytes. New merozoites
burst from the erythrocytes and infect more
cells,  leading  to  the  classic  symptoms  of
malaria  ―  paroxysms  defined  by  intense
chills, fever, and sweating. Some merozoites
mature into gametocytes outside of erythro-
cytes and are then taken up by another mos-
quito, leading to a repeat of this entire life cycle
[2,3]. Malaria also can be transmitted via blood
transfusions and organ transplants as well as
congenitally from a mother to her fetus.
There are some interspecies differences
for the Plasmodiumlife cycle. The frequency
of paroxysms can vary depending on the
speed of asexual replication and erthrocyte
bursting. P. vivax, P. malariae, and P. ovale
can all cause relapses; specifically, P. malar-
iae can persist for decades before manifest-
ing  any  symptoms  [4].  While  all  species
infect erythrocytes, only P. falciparumcan in-
fect erythrocytes in any stage of erythrocyte
development [5]. P. falciparuminfections can
thus lead to an entirely infected bloodstream
and far more frequent paroxysms than for in-
fections with other Plasmodium species.
the huMan iMMune resPonse
to Malaria 
The classic symptoms of malaria are
paroxysms defined by intense chills, fever,
and sweating. Chills will often be accompa-
nied by headaches, nausea, and fatigue. Of
course,  these  symptoms  are  common  to
many illnesses, and a definitive diagnosis re-
quires additional clinical tests and/or follow-
up  questions,  particularly  for  patients  in
non-endemic regions. In severe cases, pa-
tients may present with respiratory and neu-
rological problems as well as severe anemia
and renal failure. Cerebral malaria is a rare
complication;  it  primarily  affects  young
children, and its cause is unclear. Placental
malaria is a significant complication in en-
demic areas, but like cerebral malaria, its in-
duction is poorly understood, although gene
polymorphisms in the fetus have been found
to affect the severity of placental malaria [6].
Our poor understanding of these disease out-
comes has much to do with an incomplete
knowledge of the host immune response to
malaria and immune-evasion tactics of the
parasite. However, it also exposes a general
lack of knowledge about placental and cere-
bral  immunity.  Research  on  these  areas
should be actively encouraged.
There is little data on the human im-
mune response to malaria, such as cytokine
profiles for various strains of Plasmodium
and various disease severities, what Plas-
modium antigens are activating the innate
immune system, what innate immune recep-
tors are most relevant, and how Plasmodium
evades immune system detection [6]. The
adaptive immune response is also poorly un-
derstood. Both B cells and T cells are im-
portant  for  Plasmodium clearance.  The
Plasmodium epitopes and antigen-derived
peptides that B cells and T cells respectively
recognize have not been well characterized.
Due to the chronic nature of some Plasmod-
ium strains, it is suspected that both T cells
and B cells may be exhausted (and less func-
tional) in these patients [6]. Interestingly, a
recent study found that most patients have
functional memory B cells and long-lived
antibody  titers  (although  protectiveness
could not be assayed) [7]. Further research is
required, but this suggests that vaccines fo-
cused on activating B cells could be suc-
cessful. Additionally, depletion of regulatory
T cells (which dampen immune responses)
in mouse models of malaria enhances the
immune response to malaria [6]. Regulatory
186 Sadanand: MalariaT cell activity may thus be a good target for
drug modulation. 
There are several challenges in develop-
ing a viable, broadly effective human vaccine
to malaria. First, the most vulnerable popula-
tions (children, pregnant women, and im-
munocompromised individuals) also may be
unable to receive the vaccine or develop pro-
tective immunity from the vaccine without
booster shots. As a result, the cost of the vac-
cine could be prohibitive. Second, malaria is
endemic in regions of Africa that are already
struggling with tuberculosis and HIV infec-
tions. Co-infections make the prospect of
eliminating the parasite more difficult. Third,
Plasmodium has several life stages, making
selection of important antigens for targeting
in a vaccine more challenging. Fourth, a vac-
cine should both reduce disease on an indi-
vidual level and also lower the transmission
rate within the population; depending on what
antigens are targeted, both of these goals may
not be achieved. Finally, as indicated above,
we have a very poor understanding of the im-
mune response to malaria. Nonetheless, de-
velopment of human vaccines to malaria is
ongoing.  There  have  been  no  successful
blood stage vaccines, although use of attenu-
ated Plasmodium deficient in essential pro-
teins for merozoite have shown some promise
in mouse models of malaria [3]. The pre-ery-
throcytic stage may be more promising for
vaccine targeting; it is known that immuniza-
tion with irradiated sporozoites, which can in-
fect the liver but not undergo the liver-stage
of  development,  induces  immunological
memory [3]. As with the erythrocyte stage,
attenuated Plasmodium strains may be effec-
tive. Additionally, subunit vaccines using im-
munodominant  epitopes  also  could  be
effective. However, for vaccine development
to progress efficiently, it is vital to close the
numerous, large gaps in our understanding of
the human immune response to malaria.
Methods for diagnosing
Malaria
The simplest diagnostic test is to stain a
sample of the patient’s blood with a Ro-
manovsky stain (a broad term for eosin-meth-
ylene blue stains) and then examine it micro-
scopically.  If  the  patient  is  infected  with
malaria, Plasmodiawill be visible inside ery-
throcytes. This method is effective, particu-
larly  in  impoverished  areas,  which  lack
access to more sophisticated diagnosis meth-
ods. However, slide examination can be time-
consuming  and  somewhat  subjective;
additionally, detection limits can mean that
appropriate therapeutics are withheld for the
patient until it is too late [8]. Current data
from the World Health Organization (WHO†)
suggests that the quality and accuracy of slide
examinations is generally poor in Africa [9].
Another diagnostic method is rapid di-
agnostic tests (RDTs), in which the patient’s
blood is applied to plates or pads containing
antibodies specific for malarial antigens. If a
series of bands is visible after a short amount
of time and match bands given by a positive
control sample, the patient has malaria. Both
RDTs and microscopy can be used to deter-
mine the specific Plasmodium species the
patient harbors, but positive RDTs are typi-
cally confirmed with microscopy, as false-
positive RDTs are relatively common [10].
Enzyme-linked immunosorbent assays
(ELISAs) and polymerase chain reactions
(PCRs) also can be used to determine infec-
tion and/or past exposure to malaria, but
these techniques are substantially slower and
therefore  are  not  practical  for  use  in  the
healthcare system. However, a recent PCR-
alternative has shown some promise in early
testing. Loop-mediated isothermal amplifi-
cation (LAMP) is similar to the PCR method,
but  it  does  not  depend  on  temperature
changes to mediate amplification. Therefore,
LAMP does not require PCR blocks, which
are too expensive for impoverished areas
where malaria is endemic, and it is faster
than  traditional  PCR  [8].  Additionally,
LAMP can be modified to allow for visual
detection similar to that in an ELISA or RDT.
Primer sets have been developed that are spe-
cific for P. falciparum and for all species of
Plasmodium,  respectively.  LAMP,  using
these primer sets, was demonstrated to accu-
rately identify malaria infections in all low-
parasite  patient  isolates  tested  [8].  This
method seems to combine the advantages of
187 Sadanand: Malariaboth RDTs and microscopy, while also al-
lowing for earlier diagnoses when parasite
levels are low and, therefore, more control-
lable with drug treatments. Since primers can
be easily adjusted and are generally func-
tional at the one or two base pair mutation
level, LAMP could be a robust diagnostic
tool even in areas with rapid emergence of
drug-resistant malaria strains. LAMP will
still be relatively expensive in comparison to
microscopy, but over time may prove to be
more a cost-effective option if earlier diag-
noses can indeed be consistently achieved.
evaluation of current 
antiMalarial drugs 
There are several classes of drugs used
to treat malaria. All of these drugs target the
intraerythrocytic stage of the parasite life
cycle, when symptoms are first detectable.
Antimalarial drugs include quinolines, an-
tifolates, and artemisinin-combination thera-
pies (ACTs).
Quinolines ― quinine, chloroquinine,
mefloquine, and amodiaquine ― are basic
aromatic compounds. They are the oldest
class of antimalarial drugs. Quinine, isolated
from cinchona tree bark, has been used to
treat malaria since the early 17th century. Its
mechanism of action has not been deduced,
but it has been inferred through research on
other quinolines. All quinolines are thought
to function as hemozoin inhibitors. Hemo-
zoin is a byproduct of hemoglobin proteoly-
sis in the Plasmodium food vacuole. When
inside erythrocytes, the parasite depends on
hemoglobin proteolysis for nutrition. Heme
itself is toxic to Plasmodium, and the para-
site must therefore convert it to a non-toxic
form. The mechanism for this conversion is
unclear ― neither humans nor mosquitoes
produce hemozoin ― but this process is, ret-
rospectively, a good drug target. It has been
shown in vitro that chloroquine binds to pu-
rified heme and associates with heme-con-
taining fractions from Plasmodium, probably
competing out free heme and, thus, inhibiting
the conversion of heme to hemozoin [11].
Therefore, quinoline-resistant strains can be
inferred to have mutations in genes encoding
proteins necessary for transport of the drug
into the food vacuole of Plasmodium, and
there are at least two documented vacuole
membrane transporters that are mutated in
chloroquine-resistant strains [12]. 
Antifolates  include  sulfadoxine  and
proguanil. These drugs block steps in the
folic acid synthesis pathway, which is essen-
tial to Plasmodium growth because the par-
asite is unable to utilize pyrimidines already
synthesized by the host and must use this
pathway to make its own [12]. Antifolate re-
sistant Plasmodiumstrains contain mutations
in  dihydrofolate  reductase  and  dihy-
dropteroate synthetase, targets of proguanil
and sulfadoxine respectively [12,13]. These
mutations reduce the binding affinity of the
drugs to their targets while still enabling the
parasite to manipulate the folic acid synthe-
sis pathway for its own benefit.
ACTs  are  the  cornerstone  of  current
malaria treatments. Artemisinins are deriva-
tives of the Chinese herb Artemisia annua
that have been used since the late 1970s [14].
They are sesquiterpene lactones that reduce
the parasite load substantially earlier than
other antimalarial drugs; additionally, they
can kill Plasmodium gametes and thus lower
transmission rates [13]. Their mechanism of
action is unclear, but it is speculated that, like
quinolines, these drugs block the conversion
of heme to hemozoin [13]. Although highly
effective, artemisinins are recommended for
use in combination with the more long-last-
ing quinolines or antifolates due to their short
half-life in vivo in order to ensure complete
elimination of residual parasites. As with
other  antimalarials,  artemisinin-resistant
strains  of  Plasmodium have  already
emerged, but ACTs enhance the chance that
these  resistant  strains  can  be  contained.
WHO currently recommends ACTs as the
primary treatment for most strains of malaria
and for most patients with the exception of
pregnant women in their first trimester [9].
Methodology for antiMalarial
drug develoPMent
Good  antimalarial  drugs  should  kill
Plasmodiumin the erythrocyte infection stage
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strains [15]. Ideally, these drugs should be
easy to manufacture and safe enough for vul-
nerable  populations  such  as  children  and
pregnant women. There are currently two
major approaches to identifying antimalarial
drug candidates. In the older “whole parasite”
screening approach, chemical libraries are
created and then used to treat erythrocytes
cultured with Plasmodium [16]. Promising
drug candidates are further screened for re-
sistance before proceeding to clinical trials.
The  relatively  recent  completion  of  the
human genome sequence has enabled a sec-
ond “rational design” screening approach.
Here, molecular targets ― such as enzymes
or important receptors ― in Plasmodium are
identified, validated, and expressed before
screening with drug candidates. Since the
mechanisms of action for many antimalarial
drugs ― and, therefore, the mechanisms of
resistance against these same drugs ― are
very poorly understood, this latter approach
is  appealing.  However,  “rational  design”
screens appear to be less cost-effective than
“whole parasite” screens. Given the fast evo-
lution of Plasmodium and the slow process
for drug development, testing, and approval,
it  is  best  that  new  antimalarial  drugs  are
multi-target and the “whole parasite” screen-
ing approach facilitates this. 
Ideally, both screening approaches can be
used in tandem ― the “whole parasite” screen-
ing approach for quick generation of drug can-
didates  that  can  then  be  accelerated  into
clinical trials. During this phase, the drug could
be returned to “rational design” screens for fur-
ther identification of a mechanism of action.
Alternatively, the drug could be re-evaluated
for a mechanism of action in the “whole para-
site” screening approach by culturing with in-
creasing doses to apply selective pressure on
Plasmodiumand then sequencing the genomes
of parasites that were drug-resistant to identify
the gene mutations involved in mediating re-
sistance. The mechanism of action and poten-
tial side effects of the drug could then be
confirmed in P. berghei or P. yoelii infections
of wild-type and knock-out mice.
The  value  of  the  “whole  parasite”
screening approach was recently highlighted
by the discovery of a new class of anti-
malarial drugs ― spiroindolones ― that are
promising in a number of respects: effective
at low concentrations, easy to manufacture
and formulate, and with a clear mechanism
of action [15]. The optimized spiroindolone,
NITD609, has been tested in the P. berghei
mouse model of malaria and was found to
be effective at doses lower than those used
for  several  other  antimalarial  drugs.  By
using increasing doses of NITD609 in cul-
ture, the researchers were able to identify the
gene mutation involved in mediating resist-
ance to NITD609 and, thus, the mechanism
of action for NITD609 [15]. If NITD609
continues to be viable in clinical trials, this
information will be highly useful.
coMbating Malaria at the
level of the Mosquito
Recommended  preventive  measures
against malaria are primarily focused on
minimizing  mosquito  bites  by  following
clothing guidelines and using insecticides
and  insecticide-treated  bed  nets.  These
methods, along with preventive care during
pregnancy, are estimated to have saved al-
most three quarters of a million children in
Africa over the last 10 years [17]. Increased
investment in preventive care will save even
more lives.
Pyrethroids are the most commonly used
class of insecticides; however, many species
of Anopheles are now known to be resistant.
One long-standing controversy in preventive
care  has  been  the  use  of  the  pesticide
dichlorodiphenyltrichloroethane, more com-
monly known as DDT. DDT has been used
as a pesticide and antimalarial since the 1940s
but was found to build up in apex predators
leading to the near extinction of several bird
species in the United States. Due to its per-
sistence in the environment and its high tox-
icity, it was banned in the United States in
1972, but in 2006, the WHO once again en-
dorsed its use for malaria prevention. A re-
cent  panel  of  environmentalists  and
epidemiologists  also  recommended  DDT
with the caveat that it should be a last-resort
insecticide if safer alternatives are available
189 Sadanand: Malaria[18]. It is generally sprayed inside homes, but
there have been few studies on the implica-
tions of this for human health. The panel eval-
uated hundreds of studies to conclude that
DDT may adversely affect fertility and brain
development in children as well as increase
the risks for certain cancers and diabetes [18].
However, DDT is the most effective insecti-
cide in many regions of Africa. The panel’s
recommendations are sound; DDT remains
poorly studied, particularly in Africa, and it
is vital that constant monitoring takes place
in areas where households are being con-
stantly sprayed. It also seems inevitable that,
as with pyrethroids, DDT-resistant strains of
Anopheles eventually will emerge and re-
search should continue to focus on the devel-
opment of new, minimally toxic drugs.
The controlled eradication of Anophe-
les is an appealing idea for the prevention of
malaria and other mosquito-borne diseases,
but both its impact on the broader ecosys-
tem has been a concern. Interestingly, in a
recent Nature article that queried many mos-
quito biologists and ecologists, the scientists
were confident that the loss of the mosquito
would not adversely affect the ecosystem in
the long-term, because, somewhat surpris-
ingly,  mosquitoes  are  dispensable  and/or
easily replaceable for most of the ecological
processes they participate in [19]. Even if
mosquitoes cannot be eradicated, they are a
good vaccination target. In January 2009,
the  PATH  Malaria Vaccine  Initiative  an-
nounced a collaboration with the Sabin Vac-
cine  Institute  and  the  Johns  Hopkins
Bloomberg School of Public Health to pro-
mote the development of a transmission-
blocking vaccine (TBV). TBVs would be
administered to humans and contain key
antigens  vital  for  malaria  growth  in  and
transmission from mosquitoes. If these anti-
gens can induce a sufficiently potent, tar-
geted  antibody  response,  the  antibodies
would be taken up by mosquitoes during the
biting process and block further spread of
malaria.  Earlier  TBVs  that  have  used
malaria-specific antigens have not been suc-
cessful in clinical trials, but one recently
identified  antigen,  Anopheline alanyl
aminopeptidase 1 (AnAPN-1), appears quite
promising. AnAPN-1 is crucial for Plas-
modium invasion of the Anopheles midgut
and has had a high success rate in blocking
both P. vivax and P. falciparum development
in mosquitoes in initial trials [20]. 
Aside  from  malaria-specific  and
Anopheles-specific proteins involved directly
in malaria transmission and development in
the  mosquito,  other  good  candidates  for
TBVs could include proteins or stimuli that
could enhance the development of “innate
immune memory” in the mosquitoes, pre-
venting future infection by the parasite. “In-
nate immune memory” is likely a misnomer,
but long-lasting innate immune responses
were recently found in Anopheles gambiae
mosquitoes  [21].  Here,  mosquitoes  chal-
lenged with P. berghei had lower numbers of
oocysts in the midgut and increased numbers
of granulocytes that also were morphologi-
cally different from those in naïve mosqui-
toes, and, intriguingly, cell-free hemolymph
isolated from primed mosquitoes was pro-
tective against Plasmodiumwhen transferred
into naïve mosquitoes [21]. If the molecules
that  mediate  the  effects  of  primed  he-
molymph transfer ― increased circulating
granulocytes and oenocytoids and decreased
prohemocytes ― could be identified, they
could form the basis for a new TBV or be in-
corporated into a pre-existing TBV. 
conclusions and outlook
We are gaining ground in the battle with
both the mosquito and the Plasmodium par-
asite, but we can do better. Preventive meas-
ures  to  minimize  mosquito  bites  should
continue to be the primary focus, but there
should be increased investment in vaccine
development. Unfortunately, our poor un-
derstanding  of  the  immune  response  to
malaria is an impediment to generating good
vaccines. In order for vaccine development
to lead to viable vaccines, it is crucial that
we collect more data on immune system ac-
tivity in response to malaria, thereby poten-
tially identifying good targets for vaccine
and drug treatment. Work should continue
on TBVs and methods for combating Plas-
modium within the mosquito. These mos-
190 Sadanand: Malariaquito-intrinsic efforts may prove more valu-
able in terms of reducing transmission rates. 
The long-term efficacy of antimalarials
always will be limited due to the fast emer-
gence of drug-resistant Plasmodium strains.
Optimal drug choice should be tailored to
specific regions. As researchers have ob-
served, the most cost-effective treatments for
malaria may vary depending on antimalarial
drug resistance in a given region. Addition-
ally, a streamlined antimalarial drug design
approach would make the generation of new
drugs more efficient. Recent advances sug-
gest that the “whole parasite” screening ap-
proach is faster than the “rational design”
screening approach. Time is of the essence
as drug resistance to Plasmodium species
emerges very fast. Faster drug design does
not mean that we should abandon attempts
to understand the mechanisms of action of
these drugs, but mechanistic studies are per-
haps best conducted concurrently to the clin-
ical trial phase of drug design.
The  human  and  economic  costs  of
malaria are sometimes forgotten by those of
us fortunate to live in non-endemic regions
where malaria was eradicated long ago. Nu-
merous international and local groups are
working tirelessly to provide cohesive guide-
lines for diagnosis and treatment. Progress
may be slow, but slight shifts in funding and
research priorities could finally give us the
upper-hand against malaria. 
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